---
title: 'Irinotecan and temozolomide in combination with dasatinib and rapamycin versus
  irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma
  (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial'
date: '2024-06-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38936379/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240628182110&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Neuroblastoma is the most common extracranial solid tumour
  in children. Relapsed or refractory neuroblastoma is associated with a poor outcome.
  We assessed the combination of irinotecan-temozolomide and dasatinib-rapamycin (RIST)
  in patients with relapsed or refractory ...'
disable_comments: true
---
BACKGROUND: Neuroblastoma is the most common extracranial solid tumour in children. Relapsed or refractory neuroblastoma is associated with a poor outcome. We assessed the combination of irinotecan-temozolomide and dasatinib-rapamycin (RIST) in patients with relapsed or refractory ...